Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

NCT07190443 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

290

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Locoregional Recurrence
Abemaciclib
Endocrine Therapy

Interventions

DRUG: Endocrine therapy + Abemaciclib
DRUG: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen

Sponsor

Japanese Foundation for Cancer Research

Collaborators

[object Object]